Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis
The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future."Children and teens living with multiple sclerosis experience more
Roche's medicine Ocrevus got approval to treat young kids with multiple sclerosis. This shows the drug works for more patients, which could help the company grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.